Clinical trial
Prospective Study of Incidence and Risk Factors of Infections and of Replacement Therapy With Intravenous Immunoglobulins for Secondary Immunodeficiency in Patients With Autoimmune Diseases Treated With Rituximab
NCT03778840 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Study of Incidence and Risk Factors of Infections and of Replacement Therapy With Intravenous Immunoglobulins for Secondary Immunodeficiency in Patients With Autoimmune Diseases Treated With Rituximab
- Lead sponsor
- University Hospital, Lille
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 29, 2019
- Completion date
- May 31, 2022
- Enrollment
- 73 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.